全文获取类型
收费全文 | 1036篇 |
免费 | 52篇 |
国内免费 | 78篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 42篇 |
妇产科学 | 7篇 |
基础医学 | 131篇 |
口腔科学 | 15篇 |
临床医学 | 160篇 |
内科学 | 269篇 |
皮肤病学 | 26篇 |
神经病学 | 8篇 |
特种医学 | 287篇 |
外科学 | 29篇 |
综合类 | 23篇 |
预防医学 | 28篇 |
眼科学 | 1篇 |
药学 | 80篇 |
肿瘤学 | 59篇 |
出版年
2023年 | 2篇 |
2021年 | 7篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 14篇 |
2017年 | 8篇 |
2016年 | 10篇 |
2015年 | 12篇 |
2014年 | 15篇 |
2013年 | 20篇 |
2012年 | 27篇 |
2011年 | 12篇 |
2010年 | 27篇 |
2009年 | 39篇 |
2008年 | 23篇 |
2007年 | 71篇 |
2006年 | 13篇 |
2005年 | 24篇 |
2004年 | 11篇 |
2003年 | 25篇 |
2002年 | 13篇 |
2001年 | 22篇 |
2000年 | 25篇 |
1999年 | 35篇 |
1998年 | 67篇 |
1997年 | 73篇 |
1996年 | 52篇 |
1995年 | 63篇 |
1994年 | 36篇 |
1993年 | 35篇 |
1992年 | 18篇 |
1991年 | 22篇 |
1990年 | 17篇 |
1989年 | 38篇 |
1988年 | 35篇 |
1987年 | 24篇 |
1986年 | 28篇 |
1985年 | 47篇 |
1984年 | 19篇 |
1983年 | 13篇 |
1982年 | 26篇 |
1981年 | 16篇 |
1980年 | 26篇 |
1979年 | 7篇 |
1978年 | 5篇 |
1977年 | 14篇 |
1976年 | 15篇 |
1975年 | 9篇 |
1974年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有1166条查询结果,搜索用时 15 毫秒
61.
62.
63.
Mike G. Martin Kristan M. Augustin Geoffrey L. Uy John S. Welch Lindsay Hladnik Sagun Goyal Divya Tiwari Ryan S. Monahan Richard M. Reichley Amanda F. Cashen Keith Stockerl‐Goldstein Peter Westervelt Camille N. Abboud John F. DiPersio Ravi Vij 《American journal of hematology》2009,84(11):733-737
The current salvage therapies for relapsed/refractory acute myeloid leukemia (AML) are unsatisfactory. Over the past 7 years, we have used two salvage regimens: fludarabine, cytarabine, and idarubicin with (FLAG‐IM) or without gemtuzumab ozogamicin (GO) (9 mg/m2 on Day 8) (FLAG‐I) in relapsed/refractory AML. Three‐quarters of patients also received concurrent G‐CSF. Seventy‐one patients were treated, 23 with FLAG‐I and 48 with FLAG‐IM. The median duration of follow‐up was 30.6 months. The treatment groups were well balanced with median ages of 48 years (range 18–70) and 47 years (range 20–68), unfavorable cytogenetics in 57% and 35%, prior allogeneic stem cell transplant in 43% and 42%, and CR1 duration <1 year in 60% and 67%, respectively, for FLAG‐I and FLAG‐IM. The complete remission (CR) rate in the FLAG‐I group was 39% with an additional 13% achieving a CRp [overall response rate (ORR) 52%]; the CR rate in the FLAG‐IM group was 29% with an additional 27% achieving a CRp (ORR 56%). The median duration of response (DOR; 16.8 vs. 8.3 months), event‐free survival (EFS; 7.4 vs. 4.1 months), and overall survival (OS; 8.8 vs. 5.0 months) trended to favor FLAG‐I over FLAG‐IM. The patients who received G‐CSF concurrent with chemotherapy had superior overall response rate (ORR; 62% vs. 29%, P = 0.026), median EFS (6.2 vs. 3.4 months, P = 0.010), and OS (8.8 vs. 3.9 months, P = 0.004) when compared with those who sequentially received G‐CSF and chemotherapy, regardless of chemotherapy regimen. The addition of GO, at this dose and schedule, to FLAG‐I failed to improve the outcomes in patients with relapsed/refractory AML. The patients who received G‐CSF concurrently with chemotherapy had improved outcomes. Am. J. Hematol., 2009. © 2009 Wiley‐Liss, Inc. 相似文献
64.
Khoury H Adkins D Brown R Vij R Westervelt P Trinkaus K Goodnough LT DiPersio JF 《Bone marrow transplantation》2000,25(11):1197-1201
Administration of the myeloid growth factor G-CSF after allogeneic hematopoietic stem cell transplantation is usually well tolerated, and associated with rapid hematopoietic engraftment. We report a high incidence (50%) of side-effects associated with post-transplant G-CSF in patients with chronic phase chronic myeloid leukemia undergoing allogeneic HLA-identical sibling peripheral blood stem cell transplantation. One or more of the following signs and symptoms were observed shortly after the subcutaneous injection of G-CSF: dyspnea, chest pain, nausea, hypoxemia, diaphoresis, anaphylaxis, syncope and flushing. These reactions led to discontinuation of G-CSF in the majority of patients. Predictive factors could not be identified, and the underlying mechanism leading to these reactions is unknown. 相似文献
65.
The objective of this study was to determine whether the proposed Malan radiological sinusitis typing (RST) system facilitated a level of agreement and ease of use comparable with the Lund–Mackay (LM) system for chronic rhinosinusitis. Ten observers (one otolaryngologist and nine radiologists), in two separate centres (regional and tertiary), blinded to all clinical data, used these two systems to independently and randomly score and type 15 sets of scans, recording the time to score each film. Using unweighted kappa scores, both methods facilitated a moderate level of agreement, slightly better with the LM system. The Malan system is more time efficient. Preliminarily, this study shows that the Malan RST system is easy to apply with a comparable level of agreement. The Malan RST system is a focused attempt at classifying disease extent radiologically and correlating it to a surgical approach. It emphasizes that scoring systems are vulnerable and proves to be superior to the LM system as a surgical planning tool. To score sinus disease, a Quality‐of‐Life questionnaire in association with this typing method is more appropriate. 相似文献
66.
ER Brown KA Charles SA Hoare RL Rye DI Jodrell RE Aird R Vora U Prabhakar M Nakada RE Corringham M DeWitte C Sturgeon D Propper FR Balkwill JF Smyth 《Annals of oncology》2008,19(7):1340-1346
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response. 相似文献
67.
KA Bergman JF Meis AM Horrevorts L Monnens 《Acta paediatrica (Oslo, Norway : 1992)》1992,81(9):709-711
Systemic candidiasis with renal involvement is a rare but well-recognized complication during intensive care treatment in very-low-birth-weight infants. We report a term neonate who developed anuria associated with bilateral bezoar formation in the renal pelvis and candidemia. The treatment consisted of placement of a nephrostomy tube in the left kidney, short-term irrigation with amphotericin B and iv, and later, oral administration of fluconazole. 相似文献
68.
69.
70.
High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression 总被引:2,自引:2,他引:0
Westervelt P Lane AA Pollock JL Oldfather K Holt MS Zimonjic DB Popescu NC DiPersio JF Ley TJ 《Blood》2003,102(5):1857-1865
Transgenic mice expressing PML-RARalpha in early myeloid cells under control of human cathepsin G regulatory sequences all develop a myeloproliferative syndrome, but only 15% to 20% develop acute promyelocytic leukemia (APL) after a latent period of 6 to 14 months. However, this transgene is expressed at very low levels in the bone marrow cells of transgenic mice. Because the transgene includes only 6 kb of regulatory sequences from the human cathepsin G locus, we hypothesized that sequences required for high-level expression of the transgene might be located elsewhere in the cathepsin G locus and that a knock-in model might yield much higher expression levels and higher penetrance of disease. We, therefore, targeted a human PML-RARalpha cDNA to the 5' untranslated region of the murine cathepsin G gene, using homologous recombination in embryonic stem cells. This model produced a high-penetrance APL phenotype, with more than 90% of knock-in mice developing APL between 6 and 16 months of age. The latent period and phenotype of APL (including a low frequency of an interstitial deletion of chromosome 2) was similar to that of the previous transgenic model. Remarkably, however, the expression level of PML-RARalpha in bone marrow cells or APL cells was less than 3% of that measured in the low-penetrance transgenic model. Although the explanation for this result is not yet clear, one hypothesis suggests that very low levels of PML-RARalpha expression in early myeloid cells may be optimal for the development of APL in mice. 相似文献